1Lambda RIDe: Bringing Kinetic Readout to your Microarray
Frank Schleifenbaum,
Head of Product Management and Marketing,
Berthold Technologies GmbH & Co. KG
The Biametrics 1Lambda RIDe-technology opens the field of next generation pharmaceutical screening. Although widely established, classical fluorescence-microarray approaches suffer from some intrinsic limitations. Due to the number of incubation-, washing-, and labeling-steps involved, the technology is elaborative and time consuming and faces the risk of detecting false negatives or positives. Moreover, any access to kinetic parameters such as association and dissociation constants, being of highest relevance in pharmaceutical drug discovery, is obstructed. These limitations are overcome with the Biametrics 1Lambda-RIDe technology, exclusively featured in the Berthold bScreen reader. It brings label-free read-out to the microarray applications and combines their high-throughput of several thousands of samples with the robustness and information depth of a (SPR) label-free measurement. Relying on optical interference detection, the bScreen uses cost-efficient biochips in a standard microarray format, guaranteeing full compatibility to existing microarray environments and services. Due to the high sensitivity of the technology, versatile fields of applications are accessible, ranging from small molecules over antibodies and peptides through nanoparticles and whole cells. This makes the bScreen the ideal working horse for any molecular interaction experiment, regardless of whether a single sample is of interest or a complete library has to be screened.
|
|
